COVID-19 infection. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Control group: In the control group, only standard drugs of the national protocol are used. Intervention 2: Intervention group: In the intervention group, along with the standard drugs
Weight 25-35, 6 mg
Weight 36-50, 9 mg
Weight 51-80, 12 mg and weight over 80, 0.2 mg/kg.
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients hospitalized with suspected Covid-19 Informed consent for inclusion in study Age above 5 years Weight above 15 kg
Exclusion criteria
Exclusion criteria: Liver and kidney disease Patients with acquired immunodeficiency Consumption of warfarin and ACEI family drugs (captopril, enalapril, etc.) Breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms including fever, chills, sore throat, cough, shortness of breath, decreased appetite, abdominal pain, dizziness, insomnia, itching, joint pain, joint swelling, headache, nausea, vomiting, diarrhea, malaise, conjunctivitis, tachycardia, wheezing, rhonchus, retraction, hypotension, rash, other symptoms. Timepoint: The first, second, third, fourth, fifth, sixth, seventh day. Method of measurement: Observation and record in checklist.;Respiratory rate and O2 saturation. Timepoint: The first, second, third, fourth, fifth, sixth, seventh day. Method of measurement: Pulse Oximeter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammad Sadegh Rezai
Mazandaran University of Medical Sciences
Outcome results
None listed